Abstract
Diabetic nephropathy is a severe microvascular complication of diabetes. Qishen Yiqi dripping pill (QYDP) has been reported to be a renal protective drug. However, the mechanisms remain unclear. This study was performed to investigate the mechanisms. In this study, Sprague-Dawley rats were injected with streptozotocin to generate a diabetes model. Diabetic rats were administered 150 or 300 mg/kg/day QYDP. After 8 weeks of treatment, serum creatinine, serum blood urea nitrogen, and 24-h urinary albumin were measured. Kidney histological staining and immunostaining were analyzed. Then, the renal tissue was analyzed with a genome expression array. The results showed that QYDP treatment reduced serum creatinine, blood urea nitrogen, and 24-h urinary albumin and improved kidney histology and fibrosis. The gene array revealed that the expression of 189 genes was increased, and that of 127 genes was decreased in the high dosage QYDP group compared with the diabetic group. Pathway and gene ontology analyses showed that the differentially expressed genes were involved in the Wnt/β-catenin and transforming growth factor-β (TGF-β)/Smad2 signaling pathways. QYDP reduced the renal Wnt1, catenin β1, Tgfb1, and Smad2 gene expression and β-catenin, TGF-β, Smad2, collagen I, α-smooth muscle actin, and fibronectin protein expression in diabetic rats. Our results provide the first evidence that QYDP performs its renal-protective function by inhibiting the Wnt/β-catenin and TGF-β/Smad2 signaling pathways in diabetic rats.
Highlights
In 2019, the International Diabetes Federation announced that diabetes affects approximately 463 million people worldwide
We found that diabetic rats had significantly increased Wnt family member 1 (Wnt1), Ctnnb1, Tgfb1, and Smad2 expression in the kidney (p < 0.01, Figure 7) compared with that in the control group
This study reveals that Qishen Yiqi dripping pill (QYDP) significantly attenuates kidney function and renal fibrosis
Summary
In 2019, the International Diabetes Federation announced that diabetes affects approximately 463 million people worldwide. The number of affected individuals will reach 702 million by the year 2045 (Williams et al, 2020). Chronic tissue complications from diabetes worsen the health status of patients. Diabetic nephropathy (DN) is one of the most important microvascular complications. It. QYDP Diabetic Nephropathy Wnt/β-Catenin TGF-β is estimated that more than 20% of diabetic patients will develop chronic kidney disease (CKD) (Nelson et al, 1996). Nephropathy contributes to the development of a cardiovascular disease, resulting in increased all-cause mortality (Go et al, 2004)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
